Delivery Order SPE2DB20D9354-SPE2DB25FX7V8
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This delivery order was issued without a set-aside designation and is scheduled for completion by July 22, 2025, with performance taking place at the contractor's Park Ridge facility. The award represents a...
- The Defense Logistics Agency awarded a delivery order valued at $8,622.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, carries no set-aside designation. The award is issued under DMS Pharmaceutical Group's existing single-award Indefinite...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count packaging). This firm fixed-price delivery order, valued at $4,169.59, was awarded on August 1, 2025, with an ultimate completion date of August 4, 2025. The contract carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg tablets (120-count units) with a ceiling value of $8,339.18. This firm fixed-price delivery order, issued on September 11, 2025, with ultimate completion by September 12, 2025, represents a routine pharmaceutical supply transaction under DMS Pharmaceutical Group's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a $8,339.18 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count units). This delivery order, issued on September 24, 2025, with an ultimate completion date of September 25, 2025, carries no set-aside designation and leverages DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA under...
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg tablets (120-count). The award was made on September 17, 2025, with an ultimate completion date of September 18, 2025, under a firm fixed-price contract type with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,622.72 by the Defense Logistics Agency on August 25, 2025, for the supply of Xtandi 40 mg capsules (120-count). The contract carries no set-aside designation and is scheduled for completion by August 26, 2025. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the...
- The Defense Logistics Agency awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The delivery order, issued on July 16, 2025, with an ultimate completion date of July 17, 2025, carries firm fixed-price terms and represents a direct procurement with no set-aside designation. This award falls under DMS Pharmaceutical Group's...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units) under a firm fixed-price contract valued at $8,622.72. The contract, awarded on September 16, 2025, with an ultimate completion date of September 17, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing...
- The Defense Logistics Agency awarded a $8,339.18 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 60 tablets of Xtandi 80 mg. The award was issued on April 24, 2025, with an ultimate completion date of April 25, 2025, and carries no set-aside designation. This delivery order represents a discrete pharmaceutical supply transaction under DMS Pharmaceutical Group's larger Indefinite Delivery...
- SPE2DB20D9354Indefinite Delivery Contract
- SPE2DB20D9354-SPE2DB25FX7V8Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count units). The contract, issued on July 11, 2025, with an ultimate completion date of July 14, 2025, operates under a firm fixed-price structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA's SPE2DB program, a $499.999 billion contract vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting military healthcare facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain through consistent delivery of branded and generic prescription medications, biologics, and medical consumables to Department of Defense healthcare sites. Xtandi, an oncology treatment, represents a specialty pharmaceutical product typical of the company's portfolio, which includes high-value medications such as Tecentriq, Stelara, and various biologics. The firm fixed-price delivery order structure ensures cost certainty for the government while leveraging the company's woman-owned small business status and established distribution network to meet the Defense Logistics Agency's rapid procurement needs for military medical facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.3k | 7/11/25 |